Global X MSCI China Real Estate ETF (CHIR)
- Previous Close
12.35 - Open
12.13 - Bid --
- Ask --
- Day's Range
12.30 - 12.35 - 52 Week Range
10.98 - 20.60 - Volume
8,482 - Avg. Volume
5,052 - Net Assets 6.3M
- NAV 12.35
- PE Ratio (TTM) 4.12
- Yield 3.87%
- YTD Daily Total Return -10.09%
- Beta (5Y Monthly) 1.30
- Expense Ratio (net) 0.66%
The fund invests at least 80% of its total assets in the securities of the underlying index and in ADRs and GDRs based on the securities in the underlying index. The underlying index tracks the performance of companies in the MSCI China Index (the "parent index") that are classified in the real estate sector, as defined by the index provider. The fund is non-diversified.
Global X Funds
Fund Family
China Region
Fund Category
6.3M
Net Assets
2018-12-07
Inception Date
Performance Overview: CHIR
Trailing returns as of 3/5/2024. Category is China Region.
People Also Watch
Holdings: CHIR
Top 10 Holdings (64.41% of Total Assets)
Sector Weightings
Recent News: CHIR
Research Reports: CHIR
Analyst Report: Myriad Genetics, Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
RatingBearishPrice TargetAnalyst Report: Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
RatingBullishPrice TargetLGND: Raising target price to $66.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $66.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingNeutralPrice TargetMYGN: Lowering target price to $13.00
MYRIAD GENETICS INC has an Investment Rating of SELL; a target price of $13.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice Target